When compared with other biologic therapies, patients with psoriasis receiving IL-23 inhibitors had a lower risk for inflammatory arthritis or psoriatic arthritis development.
Patients with PsA who received bimekizumab demonstrated sustained improvements in clinical outcomes for up to 52 weeks, regardless of concomitant MTX use.
Those with a diagnosis of this condition must receive appropriate treatment. What is a person’s life expectancy with psoriatic arthritis? PsA does not usually affect life expectancy, but a ...
The Food and Drug Administration (FDA) has expanded the approval of Bimzelx ® (bimekizumab-bkzx) to include 3 new indications. In addition to plaque psoriasis, Bimzelx, a humanized interleukin-17A and ...
UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, with ...